Marker Therapeutics (NASDAQ:MRKR) Shares Down 7.5% – What’s Next?

Marker Therapeutics, Inc. (NASDAQ:MRKR)’s share price dropped 7.5% during mid-day trading on Friday . The company traded as low as $2.46 and last traded at $2.46. Approximately 48,743 shares were traded during trading, an increase of 18% from the average daily volume of 41,268 shares. The stock had previously closed at $2.66.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH boosted their target price on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research report on Monday, October 21st.

Marker Therapeutics Stock Performance

The business’s 50 day moving average is $3.38 and its two-hundred day moving average is $3.66.

Insiders Place Their Bets

In other Marker Therapeutics news, Director Steve Elms bought 11,085 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average cost of $3.20 per share, with a total value of $35,472.00. Following the completion of the acquisition, the director now owns 325,370 shares in the company, valued at $1,041,184. This trade represents a 3.53 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Enterprise Associates 16 New purchased 554,250 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average cost of $3.20 per share, for a total transaction of $1,773,600.00. Following the purchase, the insider now owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. This represents a 51.73 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 17.35% of the company’s stock.

Hedge Funds Weigh In On Marker Therapeutics

An institutional investor recently bought a new position in Marker Therapeutics stock. Invst LLC purchased a new stake in Marker Therapeutics, Inc. (NASDAQ:MRKR) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned about 0.22% of Marker Therapeutics at the end of the most recent quarter. 22.39% of the stock is currently owned by institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.